| Journal | Biomedical chromatography : BMC |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Synthetic cannabinoids (SCs) were originally synthesized to advance the understanding of the endocannabinoid system, facilitate disease research, and support the development of novel therapeutic agents. Compared with tetrahydrocannabinol, these compounds exhibit substantially higher psychoactive potency and enhanced receptor-binding affinity. The rapid and continuous evolution of SC derivatives presents significant challenges for analytical laboratories and increases the risk of misuse. Furthermore, SCs may be exploited to alter performance in both human and animal sports. The scarcity of comprehensive data regarding their toxicity, pharmacokinetics, and potential performance-enhancing mechanisms has made SCs a priority concern in recent years. This concern spans public health, forensic science, animal welfare, and sports integrity. This review examines the historical development, pharmacological properties, chemical characteristics, and physiological effects of SCs. It also presents a
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
